8.30 -
9.20 |
Registration
|
Session1:
The Promise of Nanomedicine
|
9.20 -
9.30 |
Welcome Note from Chair |
|
Ottilia Saxl, CEO, The Institute of Nanotechnology |
9.30 - 10.00 |
Keynote/Introductory Presentation |
|
Prof. Sir Michael Rawlins, Chairman, National Institute of Clinical Excellence, UK |
10.05 - 10.35 |
Nanomedicine: opportunities and roadblocks |
|
Dr Paul Smit, Senior Vice President, Philips Medical Systems |
10.40 - 11.10 |
Nanotechnology Enabled Medicines |
|
Dr Arne Hengerer, Director, Molecular MRI, Siemens Medical Solutions
|
11.15 - 11.45 |
Refreshments |
| |
|
Session 2:
Small Company Presentations
|
Chair: Dr. Paul Smit, Philips Medical Systems |
11.45 - 11.55 |
Nanobiotechnology at the Interface |
|
Dr Dale Athey, Managing Director, Orla Protein Technologies Ltd
|
12.00 -12.10 |
Functional Nanocoatings for Surface Biotechnology |
|
Dr Jas Pal Badyal, Surface Innovation Technologies |
12.15 - 12.25 |
Future non-biofouling materials by nanoscale surface modifcation |
|
Dr Tessa ten Cate, TNO Science & Industry |
12.30 - 12.40 |
Carbon coated nanomagnets for biomedical applications |
|
Dr Rudiger Klingeler, Institute of Solid State Research at IFW, Dresden, Germany |
12.45 - 12.55 |
Anti-Cancer therapy using novel gene delivery technology |
| |
Dr Andreas Schatzlein, Founder and CSO, Nanomerics |
13.00-13.55 |
Lunch |
| |
|
Session 3: Small Company Presentations
|
Chair: Dr. Leonard Fass, GE Healthcare |
|
Label-free screening of bio-molecular interactions |
|
Dr. Mathew Cooper, Founder and CEO, Akubio Ltd |
|
Nanomedicine and Infectious Diseases: the use of nanoviricides™ in the treatment of acute and chronic viral illnesses
|
|
Dr Eugene Seymour, CEO, Nanoviricides Inc,
|
| 14.30 - 14.40 |
Selective Nanoparticle Mediated Cell Killing |
|
Dr.Martin Roland Jensen, Nannovation Biotech |
14.45-15.15 |
Refreshments
|
| |
Session4:
Medical Nanotechnology - Patents, Regulation, Risks, Safety and Society
|
Chair: Ottilia Saxl, CEO, The Institute of Nanotechnology |
15.30 - 15.50 |
Keynote presentation-
Nanotechnology and risk: Insurability challenges and requirements for success |
|
Dr Thomas K Epprecht, Senior Risk Specialist, Swiss Reinsurance Company |
15.55 - 16.15 |
An Introduction to Patents in Nanotechnology |
|
Mr Hilton Lord, Partner, Marks&Clerk |
16.20 - 16.30 |
EMEA’s reflection on nanotechnology-based medicinal products for Human Use |
|
Dr Marisa Papaluca Amati, Deputy Head of Sector, European Medicines Agency (EMEA) |
16.35 - 16.45 |
Lead Aerosol Size Distribution and Occupational Health |
|
Dr Robert Muir, Innospan |
16.50 - 17.45 |
Panel Discussion |
17.45 - 17.50 |
Closing Remarks |
17.50 - 19.00 |
Networking |
19.00 - 22.30 |
Event Dinner |
|
8.30 - 9.00 |
Registration
|
Session5:
The Promise of Nanomedicine II
|
9.00 - 9.15 |
Welcome Note from Chair |
|
Prof Shervanthi Homer Vanniasinkam, Vascular Institute, The General Infirmary,Leeds |
9.15 - 9.45 |
Keynote Presentation-The Role of Nanotechnology in Healthcare
|
|
Dr Leonard Fass, Director, Academic Relations, GE Healthcare |
9.50 - 10.20 |
‘Bionanotechnology in Australia’ |
|
Dr Bob Irving, Scientific and Commercial Director, Nanotechnology Victoria Pty Ltd, Australia |
| 10.25 - 11.00 |
Refreshments |
| |
|
Session 6:
Small Company Presentations - Nanotechnology in Diagnostics, Imaging
|
| Chair: Dr. Robert Porter, NPL Biotech Group |
11.00 - 11.10 |
Novel Piezoelectric film technology for diagnostic applications |
|
Dr Neil Butler, CEO, Vivacta |
11.15 - 11.25 |
Electronic Nose Technology for the early detection of TB |
| |
Dr. Tim Gibson, R & D Director, Scensive Technologies Limited |
11.30 - 11.40 |
Anti-Viral Nanomaterial Targetted at Pandemic Viruses |
|
Dr. Paul Reip, CEO, Qinetiq Nanomaterials |
11.45 - 11.55 |
Nanoplex ™ Biotags: A Transformational Optical Detection Platform for Clinical and Point-Of-Care Diagnostics |
|
Dr Peter Corish, Applications Manager Biodiagnostics, Oxonica Healthcare |
12.00 - 12.10 |
Endomagnetics: Making Magnets Work For Healthcare |
|
Prof. Quentin Pankhurst, Deputy Director, London Centre for Nanotechnology, and Co-Founder, Endomagnetics Inc. |
12.15 - 12.25 |
Nanoparticles for the Next generation of Rapid Tests |
|
Dr Maryam Mehrabi, University of Liverpool |
| 12.30 -13.45 |
Lunch |
| |
Session 7:
Investing in Medical Nanotechnologies - Evaluation, Finances and Challenges
|
| Moderator - Del Stark, CEO, European Nanotechnology Trade Alliance |
13.45 - 14.05 |
Keynote presentation -
Medical Nanotechnology: Business Models, Financing and Valuation |
|
Dr. Ogan Gurel, CEO, Duravest Inc |
14.10 - 14.30 |
Keynote presentation -
EIB financing of Research, Development and Innovatrion Projects |
|
Dr Kim Kreilgaard, Head of Division, European Investment Bank
|
14.35 - 14.45 |
Are you ready for investment? |
|
Paula Knee, Quotec Ltd |
14.50 - 15.00 |
Industry Reputation and Investment Risks |
|
Dr John Browne, Strategic Advantage |
15.05 - 15.15 |
The Role of Technology Roadmaps in Making Investment Decisions in Nanotechnology |
|
Dr Malcolm Wilkinson, Manging Director, Technology for Industry Ltd |
15.20 - 15.50 |
Panel Discussion: Investing in Medical Nanotechnologies – Evaluation, Finances and Challenges
|
|
Panel: Dr Ogan Gurel, Duravest Inc.; Dr Kim Kreilgaard, EIB; Paula Knee, Quotec Ltd; Dr John Browne, Strategic Advantage; Dr Malcolm Wilkinson, TFI Ltd.
|
| |
|
15.50 - 16.00 |
Conference Close |
Updated: 12/12/06 |
